Loading clinical trials...
Loading clinical trials...
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Conditions
Interventions
KL1333
Placebo
Locations
23
United States
Akron Children's Hospital
Akron, Ohio, United States
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven Gasthuisberg Campus
Leuven, Belgium
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Denmark
Start Date
December 13, 2022
Primary Completion Date
October 1, 2027
Completion Date
November 1, 2027
Last Updated
October 9, 2025
Lead Sponsor
Abliva AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions